iBio, Inc. filings document material events for an AI-driven biotechnology company developing precision antibody therapies. Recent Form 8-K disclosures cover clinical and regulatory updates for IBIO-600, preclinical data for IBIO-610, quarterly financial results, Regulation FD communications and other pipeline-related events.
The company's filings also record capital-structure matters involving common stock, pre-funded warrants and Series G warrants, along with shareholder voting results, board composition, committee appointments and governance items disclosed through annual-meeting and material-event reports.
iBio, Inc.’s Chief Financial Officer Felipe Duran purchased 24,835 shares of common stock in the open market. The transactions occurred on March 19, 2026 at prices ranging from $2.01 to $2.02 per share, with a weighted average purchase price of $2.0186.
Following these purchases, Duran directly owns 35,974 shares of iBio common stock. The filing notes that the shares were acquired through multiple trades within the price range, and the CFO has committed to provide detailed trade breakdowns upon request.
iBio, Inc. director and officer Martin Brenner bought 12,336 shares of common stock in an open-market transaction at $2.02 per share. This was a direct purchase, classified as a routine open-market buy.
Following this transaction, Brenner directly owns 30,652 shares of iBio common stock.
iBio, Inc. filed a Form 8-K describing new preclinical results for IBIO-610, an Activin E antibody candidate being studied for fat-selective weight loss. In obese non-human primates, two once-every-eight-week doses reduced visceral fat by 6.7% and total fat mass by 5.2% despite a high-calorie diet, with only a slight increase in lean mass.
These findings, consistent with prior rodent data and other Activin E–targeting approaches in human trials, support continued evaluation of IBIO-610 for obesity, cardiometabolic and cardiopulmonary diseases. iBio also highlighted strategic expansion into the cardiopulmonary field, including a myostatin x Activin A bispecific antibody program for pulmonary hypertension heart failure with preserved ejection fraction (PH-HFpEF), in an updated corporate presentation.
iBio, Inc. has filed a prospectus supplement to offer up to $100,000,000 of its common stock in an at-the-market offering through Jefferies LLC acting as sales agent.
Sales may occur from time to time under a Sales Agreement dated February 27, 2026, with commissions up to 3.0%. The prospectus states 34,543,561 shares outstanding as of February 24, 2026. Net proceeds, if any, are intended for working capital and general corporate purposes, including potential acquisitions, licensing, or repurchases.
iBio, Inc. entered into a new at-the-market stock offering program with Jefferies LLC, allowing sales of up to $100,000,000 of common stock under a new Form S-3 shelf registration statement, when declared effective. The company will control sale parameters such as timing, size per trading day, and minimum price, while paying Jefferies a commission of up to 3.0% of gross proceeds plus specified legal and filing-related fees.
iBio also terminated its prior at-the-market program with Chardan Capital Markets and Craig-Hallum Capital Group, which had permitted issuances of up to $7,350,000 of common stock. No further sales will occur under the prior agreement or its related prospectus.
iBio, Inc. filed a shelf registration on Form S-3 to offer up to $200,000,000 of securities, including up to $100,000,000 of Common Stock that may be offered under an Open Market Sales Agreement with Jefferies LLC dated February 27, 2026, to be sold from time to time as market conditions permit.
The prospectus states the offering may include Common Stock, Preferred Stock, debt securities, warrants or units. As context, the company reported 34,543,561 shares outstanding as of February 24, 2026 and 127,598,048 shares issuable upon exercise of outstanding warrants as of February 24, 2026.
iBio, Inc. received an updated Schedule 13G/A from ADAR1 Capital Management, related entities, and Daniel Schneeberger reporting beneficial ownership of up to 1,351,671 shares of common stock, or 4.4% of the company’s shares outstanding as of December 31, 2025.
The position includes 390,864 shares held by ADAR1 Partners, LP, smaller amounts in other managed accounts, and 956,140 shares underlying milestone warrants. The filers state the securities are held in the ordinary course of business and not for changing or influencing control, and they now report ownership of 5 percent or less of the class.
iBio, Inc. received an amended Schedule 13G filing showing that Logos Global Management LP and affiliated entities report beneficial ownership of 1,500,000 shares of iBio common stock. This stake represents 4.6% of the outstanding common shares, based on 32,540,942 shares outstanding as of January 30, 2026, as cited from iBio’s Form S-3.
The filing attributes the same 1,500,000-share, 4.6% position to Logos Global Management LP, Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and Arsani William, with shared voting and dispositive power over all reported shares and no sole power. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of iBio. They also jointly file while expressly disclaiming group status and beneficial ownership beyond their pecuniary interest.
iBio, Inc. received an amended Schedule 13G/A from Lynx1 Capital Management LP and Weston Nichols stating they no longer beneficially own any of the company’s common stock. The filing reports 0 shares beneficially owned and a 0% ownership stake, with no voting or dispositive power over any shares.
The reporting persons also certify that the securities referenced were not acquired and are not held for the purpose of changing or influencing control of iBio, Inc., and are not part of any control-related transaction.